Our unique infectious disease perspective comes from an integrated team approach, with experts spanning every stage of the drug development process, ensuring your project will be enriched with valuable insights from a diverse range of perspectives. As every infectious disease and project is different, we employ a variety of data sources and methodology to produce evidence which best meets our client needs.
Our teams deliver optimised, robust analysis, benefiting from diverse, comprehensive knowledge spanning all corners of infectious diseases.
The combination of technical accuracy and clear, concise, simple-to-understand scientific communications, makes us the perfect partner to work with.
In indications where continuous developments are taking place, we provide efficient updates using bespoke time-saving innovations to ensure our clients have up-to-date results as soon as possible. Whether for a fixed (one-off deliverable) or repeated deliverables with each data read-out, we have your needs covered.
940+
Projects in infectious diseases
99+
Infectious disease manuscripts
44+
Infectious disease indications
28+
Clients
We have expertise in a wide range of modelling techniques and employ the most appropriate combination of approaches to comprehensively address your research question.
We are fully equipped to design and conduct infectious disease modelling projects.
With experience spanning a number of infectious disease indications, our in-house team of Statisticians and Epidemiologists have the technical expertise to deliver complex modelling methods to meet the needs of your project.
We develop differential equations to model transition of patients through disease states, tailoring each model to the relevant indication, with input from external experts for validation of the modelling approach.
With expertise in data visualisation software (such as R and Python), we produce reports that are not only technically accurate and informative, but visually appealing.
Discover the impact of the elderly RSV vaccine roll out in England through our latest analysis. With the introduction of vaccines, older adults now have greater protection against severe RSV infections. Our analysis explores initial elderly RSV vaccine uptake in England, its effects on hospitalisation rates, and the future implications for public health. Learn how these advances could shape seasonal vaccination strategies and potentially reduce the healthcare burden.
